SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study)

PHASE4CompletedINTERVENTIONAL
Enrollment

324

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2010

Conditions
Coronary DiseaseCoronary Artery DiseaseCoronary Restenosis
Interventions
DEVICE

TAXUS® Liberté™

Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes

DEVICE

XIENCE V® EECSS

Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes

Trial Locations (28)

Unknown

Salzburger Landeskliniken, Salzburg

C.H.U. - Hopital Michallon, Grenoble

CHU Lille - Hôpital Cardiologique, Lille

Herzzentrum, Bernau

Universitätsklinikum, Heidelberg

Lukas Krankenhaus Neuss, Neuss

Herzzentrum Siegburg GmbH, Siegburg

Sheba Medical Center, Ramat Gan

Azienda Ospedaliera Riuniti, Bergamo

Ospedale Civile, Mirano

Azienda Ospedaliera di Padova, Padua

IRCCS Policlinico San Matteo, Pavia

Azienda Ospedaliera S. Gdi Dio Salerno, Salerno

Institute Jantung Negara, Kuala Lumpur

Medisch Centrum Alkmaar, Alkmaar

Maasstad Ziekenhuis, Rotterdam

Medical University of Bydgoszcz, Bydgoszcz

General De Alicante, Alicante

Hospital Belvigte de Barcelona, Barcelona

Hospital Santa Creu I Sant Pau, Barcelona

Clinico San Carlos, Madrid

Hospital Puerta de Hierro, Madrid

La Paz, Madrid

Hospital Virgen de la Arrixaca, Murcia

Hospital General de Valencia, Valencia

King Chulalongkorn Memorial Hospital, Bangkok

King's College Hospital, London

SO16 6YD

Wessex Cardiac Unit, Southampton

Sponsors
All Listed Sponsors
lead

Abbott Medical Devices

INDUSTRY